Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Sarcoma 3Neoplasms 3Brain Neoplasms 3Thyroid Carcinoma, Anaplastic 2Sarcoma, Synovial 2Prostatic Neoplasms 2Neurofibrosarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Gliosarcoma 2Glioblastoma 2Dermatofibrosarcoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Somatostatinoma 1Solid Neoplasm 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Recurrent Uterine Corpus Sarcoma 1Recurrent Lymphoepithelioma of the Nasopharynx 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Ovarian Neoplasms 1

Interventions

gallium Ga 68 dotatate 3Specimen Handling 3Temozolomide 2Magnetic Resonance Spectroscopy 2talazoparib 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1guadecitabine 1cixutumumab 1Salts 1Octreotide 1Nivolumab 1Ipilimumab 1Fluorodeoxyglucose F18 1Everolimus 1Contrast Media 1CTLA-4 Antigen 1Biopsy 1Axitinib 1Acetates 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Paraganglioma × pazopanib × Clear all
NCT01340794 2017-09-21

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

National Cancer Institute (NCI)

Phase 2 Terminated
7 enrolled 8 charts
CNSEndocrine

Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡